Abstract | BACKGROUND: Results of previous studies on the safety and efficacy of adjunctive reboxetine for schizophrenia have been inconsistent. AIM: The aim of this study was to examine the efficacy and tolerability of reboxetine as an adjunct medication to antipsychotic treatment in a meta-analysis of randomized controlled trials (RCTs). METHODS: Two independent investigators extracted data for a random effects meta-analysis and assessed the quality of studies using risk of bias and the Jadad scale. Weighted and standardized mean differences (WMDs/SMDs) and risk ratio (RR)±95% confidence intervals (CIs) were calculated. RESULTS: Nine RCTs (n=630) with double-blind design were identified. Reboxetine outperformed placebo in improving negative (9 RCTs, n=602, SMD: -0.47 [95% CI: -0.87, -0.07], p=0.02; I2=82%), but not the overall, positive, and general psychopathology scores. The significant therapeutic effect on negative symptoms disappeared in the sensitivity analysis after removing an outlying study and in 50% (6/12) of the subgroup analyses. Reboxetine outperformed placebo in reducing weight (3 RCTs, n=186, WMD: -3.83 kg, p=0.04; I2=92%) and body mass index (WMD: -2.23 kg/m2, p=0.04; I2=95%). Reboxetine caused dry mouth but was associated with less weight gain overall and weight gain of ≥7% of the initial weight. All-cause discontinuation and other adverse events were similar between reboxetine and placebo. CONCLUSION:
|
Authors | Wei Zheng, Xian-Bin Li, Zhan-Ming Shi, Xin-Hu Yang, Dong-Bin Cai, Chee H Ng, Gabor S Ungvari, Wei-Jian Liu, Yu-Jie Wu, Yuan-Yuan Wang, Yu-Ping Ning, Yu-Tao Xiang |
Journal | Pharmacopsychiatry
(Pharmacopsychiatry)
Vol. 53
Issue 1
Pg. 5-13
(Jan 2020)
ISSN: 1439-0795 [Electronic] Germany |
PMID | 31207653
(Publication Type: Journal Article, Meta-Analysis)
|
Copyright | © Georg Thieme Verlag KG Stuttgart · New York. |
Chemical References |
- Antipsychotic Agents
- Reboxetine
|
Topics |
- Adult
- Antipsychotic Agents
(administration & dosage, adverse effects, therapeutic use)
- Body Mass Index
- Cognition
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Humans
- Male
- Middle Aged
- Patient Dropouts
- Randomized Controlled Trials as Topic
- Reboxetine
(administration & dosage, adverse effects, therapeutic use)
- Schizophrenia
(drug therapy)
|